Insightec, a global leader in focused ultrasound technology, has announced the launch of Lotus Neuro, a new clinical stage biotechnology company dedicated to advancing brain-targeted therapies using precision, low-frequency focused ultrasound. The spin-out marks a key step in merging Insightec’s world-class device technology with Lotus Neuro’s innovative drug development model to enhance delivery of therapies across the blood-brain barrier. Insightec’s focused ultrasound platform has already demonstrated safety, achieved global adoption, and attracted growing interest from pharmaceutical partners. The creation of Lotus Neuro allows Insightec to focus on scaling and advancing the device platform while Lotus Neuro applies the technology to develop next-generation therapeutics in areas such as neuro-oncology and neurodegeneration.
Health Technology Insights: MHK Launches SmartProminence AI Solutions
“This is a pivotal moment for brain health innovation,” said Maurice R. Ferré, MD, Chairman and CEO of Insightec. “Insightec will continue to expand its precision ultrasound platform while Lotus Neuro applies it to new therapeutic areas in oncology and neurodegeneration. Together we are building a full ecosystem from device to drug delivery that can redefine treatment possibilities in neuroscience.”
Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR
Lotus Neuro will initially prioritize clinical neuro-oncology programs, including glioblastoma and diffuse midline gliomas, while advancing pre-clinical programs and partnerships for neurodegenerative disorders. The company is backed by Nexus NeuroTech Ventures, which focuses on technologies targeting brain disorder diagnosis, treatment, and management.
Arjun JJ Desai, MD, formerly Chief Strategic Innovation Officer at Insightec, has been named CEO of Lotus Neuro. Dr. Desai led global market access, medical affairs, research infrastructure, and strategic partnerships in therapeutic delivery using focused ultrasound across neurological conditions. “Lotus Neuro is dedicated to turning brain-targeted therapies into a reality,” Desai said. “By combining focused ultrasound with cutting-edge therapeutics, we aim to create new treatment pathways for complex brain diseases. Building on Insightec’s leadership, Lotus Neuro bridges technological innovation with meaningful therapeutic impact.”
Insightec will continue leading in device innovation while supporting Lotus Neuro through platform integration, scientific collaboration, and shared translational data. Both organizations will pursue a unified goal of making incisionless brain-targeted therapies accessible worldwide.
This initiative builds on Insightec’s recent achievements, including regulatory approvals for treating essential tremor and Parkinson’s disease and a multicenter glioblastoma study published in The Lancet Oncology. The study demonstrated that temporarily opening the blood-brain barrier with focused ultrasound during chemotherapy improved overall survival, highlighting the potential of this platform to enhance outcomes in brain-targeted therapies.
Health Technology Insights: First Stop Health Joins ParetoHealth Network
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
